Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 June;64(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 June;64(2):203-10

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 June;64(2):203-10

DOI: 10.23736/S1824-4785.18.03039-X

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Serotonin 1A receptor density measured by F18-Mefway PET/CT in mesiotemporal cortex and raphe does not discriminate therapeutic response in patients with major depressive episode

Martin BARTH 1, Andreas DUNZINGER 2, Irina WIMMER 2, Johanna WINKLER 1, Hans RITTMANNSBERGER 1, 3, Michael NADER 4, Robert PICHLER 2, 5, 6

1 Department of Psychiatry, Neuromed Campus, Kepler University Hospital, Linz, Austria; 2 Institute of Nuclear Medicine, Neuromed Campus, Kepler University Hospital, Linz, Austria; 3 Department of Psychiatry, Gespag Hospital Steyr, Steyr, Austria; 4 Advanced Accelerator Applications Germany, Bonn, Germany; 5 Institute of Nuclear Medicine, Gespag Hospital Steyr, Steyr, Austria; 6 Department of Radiology, Clinic of Nuclear Medicine, Medical University Graz, Graz, Austria



BACKGROUND: More than 50% of patients with major depressive episode (MDE) fail to respond to initial treatment with first line pharmacological therapy. Altered receptor and serotonin transporter function are considered to be associated with mental disorders. Our investigation aimed on the density of the HT1A receptor in mesiotemporal cortex (MTC) and raphe measured by F18-Mefway in patients with MDD.
METHODS: Patients with untreated clinically suspected major depressive episode were recruited from June 2012 to May 2014. 49 patients were included into the study: 36 patients (73%) were identified as responders, whereas 13 (27%) were non-responders. Gender distribution was 26 men (56%) and 23 women (44%). For treatment, only a standard medication of a selective serotonin reuptake inhibitor (SSRI) with escitalopram in a range of 10-20 mg/day was permitted. Responders were defined by improvement of the MADRS>50%. Visually MTC had the highest uptake of F18-Mefway among all brain regions, an asymmetry could not be observed in any patient. An elliptical region was drawn over the amygdala and hippocampus area and a small circular region was drawn over the raphe nuclei. All data were calculated related to (unspecific) cerebellar uptake.
RESULTS: The quotient of the right MTC was 5.00 [4.33; 5.50] in all patients, in responders 5.00 [4.00; 5.75] and in non-responders 5.00 [4.50; 5.50] (P=0.56). The quotient of the left MTC presented with a median level of 4.50 [4.50; 5.50] in all persons. The responders had 4.50 [4.50; 5.75] which was not statistically significant to the data of the non-responders with 5.00 [4.50; 5.50] at P=0.64. The raphe had a median quotient of 2.50 [2.00; 3.00] in all and the cohort of responders, whereas non-responders had 2.50 [2.00; 2.50] (P=0.61). Also the absolute values of SUV in the three brain regions were not statistically different between the cohorts. Additionally, we did not find any sex-related differences in our patient group.
CONCLUSIONS: Serotonin 1A receptor density can be assessed efficiently by F18-Mefway and PET-CT in patients with MDE. The method can be estimated as a possible tool for clinical and academic investigation, marked tracer uptake can constantly be observed at MTC and the raphe. Anyhow, under conditions of real life in patient care, it is not possible to distinguish patients with a good prognosis who will respond to standard SSRI therapy from non-responders who would benefit from a different therapeutic approach starting earlier.


KEY WORDS: Receptors, serotonin; Mefway; Positron emission tomography/computed tomography

inizio pagina